Bashir Ahmed, MD
Family Medicine · Selden, NYNPI 1891864773
Payments from drug & device makers
Across 84 payments — averaging $16.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Orexo US, Inc.$321
- Novo Nordisk$252
- AbbVie$226
- Pfizer$92
- Exact Sciences$79
- Boehringer Ingelheim$78
- plus $311 from 11 others
Across 1 payment — averaging $150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$150
What the payments were for
- Food & beverage$1,360100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Orexo US, Inc. | 19 | $321 |
| Novo Nordisk | 25 | $252 |
| AbbVie(2 entities) | 11 | $226 |
| Pfizer | 5 | $92 |
| Exact Sciences | 4 | $79 |
| Boehringer Ingelheim | 4 | $78 |
| Lilly USA, LLC | 4 | $70 |
| AstraZeneca | 2 | $43 |
| Boston Scientific | 1 | $38 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $37 |
| Amgen | 1 | $28 |
| Evoke Pharma, Inc. | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Novartis | 1 | $13 |
| Indivior Inc. | 1 | $12 |
How this compares
$1,360 in reported general payments places this provider in the 70th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 44 | $7,338 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 41 | $1,128 |
| Metoprolol Succinate | 46 | $863 |
| Ultra-Fine Short Pen NeedlePen Needle, Diabetic | 15 | $725 |
| Levothyroxine Sodium | 74 | $625 |
| Metformin Hcl | 111 | $577 |
| Lisinopril | 91 | $438 |
| Simvastatin | 99 | $375 |
| Amlodipine Besylate | 69 | $333 |
| Rosuvastatin Calcium | 32 | $316 |
| Fluticasone Propionate | 35 | $304 |
| Omeprazole | 29 | $297 |
| Pantoprazole Sodium | 30 | $264 |
| Gabapentin | 13 | $252 |
| Tamsulosin Hcl | 27 | $233 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Selden
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.